222 related articles for article (PubMed ID: 31018250)
21. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals.
Tarazona R; Casado JG; Delarosa O; Torre-Cisneros J; Villanueva JL; Sanchez B; Galiani MD; Gonzalez R; Solana R; Peña J
J Clin Immunol; 2002 May; 22(3):176-83. PubMed ID: 12078859
[TBL] [Abstract][Full Text] [Related]
22. CD56
Chen T; Liu C; Li L; Liu H; Wang T; Shao Z; Fu R
Int J Lab Hematol; 2019 Jun; 41(3):353-363. PubMed ID: 30779419
[TBL] [Abstract][Full Text] [Related]
23. CD56
Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
[TBL] [Abstract][Full Text] [Related]
24. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation.
Dulphy N; Haas P; Busson M; Belhadj S; Peffault de Latour R; Robin M; Carmagnat M; Loiseau P; Tamouza R; Scieux C; Rabian C; Di Santo JP; Charron D; Janin A; Socié G; Toubert A
J Immunol; 2008 Aug; 181(3):2227-37. PubMed ID: 18641363
[TBL] [Abstract][Full Text] [Related]
25. Anti-CTLA-4 therapy for malignant mesothelioma.
Guazzelli A; Bakker E; Krstic-Demonacos M; Lisanti MP; Sotgia F; Mutti L
Immunotherapy; 2017 Mar; 9(3):273-280. PubMed ID: 28231719
[TBL] [Abstract][Full Text] [Related]
26. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Maio M; Scherpereel A; Calabrò L; Aerts J; Perez SC; Bearz A; Nackaerts K; Fennell DA; Kowalski D; Tsao AS; Taylor P; Grosso F; Antonia SJ; Nowak AK; Taboada M; Puglisi M; Stockman PK; Kindler HL
Lancet Oncol; 2017 Sep; 18(9):1261-1273. PubMed ID: 28729154
[TBL] [Abstract][Full Text] [Related]
27. CD56
Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
[TBL] [Abstract][Full Text] [Related]
28. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.
Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M
Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry.
Ranganath T; Simpson LJ; Ferreira AM; Seiler C; Vendrame E; Zhao N; Fontenot JD; Holmes S; Blish CA
Front Immunol; 2020; 11():714. PubMed ID: 32391016
[TBL] [Abstract][Full Text] [Related]
30. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.
Dunne J; Lynch S; O'Farrelly C; Todryk S; Hegarty JE; Feighery C; Doherty DG
J Immunol; 2001 Sep; 167(6):3129-38. PubMed ID: 11544298
[TBL] [Abstract][Full Text] [Related]
31. Natural Killer and Natural Killer T Cells in Juvenile Systemic Lupus Erythematosus: Relation to Disease Activity and Progression.
Zahran AM; Abdel-Rahim MH; Elsayh KI; Hassanien MM; Mahran SA; Hetta HF
Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):161-169. PubMed ID: 30944972
[TBL] [Abstract][Full Text] [Related]
32. The Increased Ratio of Blood CD56
Ming B; Wu T; Cai S; Hu P; Tang J; Zheng F; Ye C; Dong L
J Immunol Res; 2020; 2020():7523914. PubMed ID: 32695834
[TBL] [Abstract][Full Text] [Related]
33. Highly activated TRAIL
Jiang Y; Qin S; Wei X; Liu X; Guan J; Zhu H; Chang G; Chen Y; Lu H; Qian J; Wang Z; Shen M; Lin X
Immunol Lett; 2021 Apr; 232():9-19. PubMed ID: 33515618
[TBL] [Abstract][Full Text] [Related]
34. Participation of the CD94 receptor complex in costimulation of human natural killer cells.
Voss SD; Daley J; Ritz J; Robertson MJ
J Immunol; 1998 Feb; 160(4):1618-26. PubMed ID: 9469418
[TBL] [Abstract][Full Text] [Related]
35. IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56
Dubois S; Conlon KC; Müller JR; Hsu-Albert J; Beltran N; Bryant BR; Waldmann TA
Cancer Immunol Res; 2017 Oct; 5(10):929-938. PubMed ID: 28842470
[TBL] [Abstract][Full Text] [Related]
36. Multicolor flow cytometric analysis of TLR2 and TLR9 expression and function in NK cells from patients with ANCA-associated vasculitis.
Scrivo R; Peruzzi G; Gattamelata A; Gross CC; Carletti R; Di Gioia C; Brandt J; Priori R; Morrone S; Santoni A; Valesini G
Cytometry B Clin Cytom; 2018 May; 94(3):412-422. PubMed ID: 28834234
[TBL] [Abstract][Full Text] [Related]
37. Activation of human T cells with NK cell markers by staphylococcal enterotoxin A via IL-12 but not via IL-18.
Ami K; Ohkawa T; Koike Y; Sato K; Habu Y; Iwai T; Seki S; Hiraide H
Clin Exp Immunol; 2002 Jun; 128(3):453-9. PubMed ID: 12109440
[TBL] [Abstract][Full Text] [Related]
38. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
39. Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: Reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity.
Phan MT; Chun S; Kim SH; Ali AK; Lee SH; Kim S; Kim SH; Cho D
Hum Immunol; 2017 Feb; 78(2):103-112. PubMed ID: 27884732
[TBL] [Abstract][Full Text] [Related]
40. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
Esen F; Deniz G; Aktas EC
Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
